97 related articles for article (PubMed ID: 38732063)
41. Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.
Kashima Y; Shibahara D; Suzuki A; Muto K; Kobayashi IS; Plotnick D; Udagawa H; Izumi H; Shibata Y; Tanaka K; Fujii M; Ohashi A; Seki M; Goto K; Tsuchihara K; Suzuki Y; Kobayashi SS
Cancer Res; 2021 Sep; 81(18):4835-4848. PubMed ID: 34247147
[TBL] [Abstract][Full Text] [Related]
42. Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells.
Mohan A; Raj Rajan R; Mohan G; Kollenchery Puthenveettil P; Maliekal TT
Front Cell Dev Biol; 2021; 9():668851. PubMed ID: 34150761
[TBL] [Abstract][Full Text] [Related]
43. The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition.
Daum S; Hagen H; Naismith E; Wolf D; Pircher A
Front Cell Dev Biol; 2020; 8():610903. PubMed ID: 33469537
[TBL] [Abstract][Full Text] [Related]
44. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
Le X; Nilsson M; Goldman J; Reck M; Nakagawa K; Kato T; Ares LP; Frimodt-Moller B; Wolff K; Visseren-Grul C; Heymach JV; Garon EB
J Thorac Oncol; 2021 Feb; 16(2):205-215. PubMed ID: 33096270
[TBL] [Abstract][Full Text] [Related]
45. Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets.
Wei N; Song Y; Zhang F; Sun Z; Zhang X
Front Oncol; 2020; 10():1424. PubMed ID: 32923394
[No Abstract] [Full Text] [Related]
46. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
Nilsson MB; Sun H; Robichaux J; Pfeifer M; McDermott U; Travers J; Diao L; Xi Y; Tong P; Shen L; Hofstad M; Kawakami M; Le X; Liu X; Fan Y; Poteete A; Hu L; Negrao MV; Tran H; Dmitrovsky E; Peng D; Gibbons DL; Wang J; Heymach JV
Sci Transl Med; 2020 Sep; 12(559):. PubMed ID: 32878980
[TBL] [Abstract][Full Text] [Related]
47. TGFβ-Directed Therapeutics: 2020.
Teicher BA
Pharmacol Ther; 2021 Jan; 217():107666. PubMed ID: 32835827
[TBL] [Abstract][Full Text] [Related]
48. 3D culture technologies of cancer stem cells: promising ex vivo tumor models.
Zhang C; Yang Z; Dong DL; Jang TS; Knowles JC; Kim HW; Jin GZ; Xuan Y
J Tissue Eng; 2020; 11():2041731420933407. PubMed ID: 32637062
[TBL] [Abstract][Full Text] [Related]
49. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.
Shah R; Lester JF
Clin Lung Cancer; 2020 May; 21(3):e216-e228. PubMed ID: 32014348
[TBL] [Abstract][Full Text] [Related]
50. EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies.
Zhu X; Chen L; Liu L; Niu X
Front Oncol; 2019; 9():1044. PubMed ID: 31681582
[TBL] [Abstract][Full Text] [Related]
51. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition in Cancer Metastasis.
Celià-Terrassa T; Jolly MK
Cold Spring Harb Perspect Med; 2020 Jul; 10(7):. PubMed ID: 31570380
[TBL] [Abstract][Full Text] [Related]
52. Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer.
Wang C; Wang T; Lv D; Li L; Yue J; Chen HZ; Xu L
Mol Cancer Ther; 2019 Dec; 18(12):2357-2367. PubMed ID: 31501278
[TBL] [Abstract][Full Text] [Related]
53. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
Becker JH; Gao Y; Soucheray M; Pulido I; Kikuchi E; Rodríguez ML; Gandhi R; Lafuente-Sanchis A; Aupí M; Alcácer Fernández-Coronado J; Martín-Martorell P; Cremades A; Galbis-Caravajal JM; Alcácer J; Christensen CL; Simms P; Hess A; Asahina H; Kahle MP; Al-Shahrour F; Borgia JA; Lahoz A; Insa A; Juan O; Jänne PA; Wong KK; Carretero J; Shimamura T
Cancer Res; 2019 Sep; 79(17):4439-4452. PubMed ID: 31273063
[TBL] [Abstract][Full Text] [Related]
54. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.
Hao Y; Baker D; Ten Dijke P
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195692
[TBL] [Abstract][Full Text] [Related]
55. Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway.
Song YA; Ma T; Zhang XY; Cheng XS; Olajuyin AM; Sun ZF; Zhang XJ
Cancer Cell Int; 2019; 19():117. PubMed ID: 31073278
[TBL] [Abstract][Full Text] [Related]
56. Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance.
Gupta PB; Pastushenko I; Skibinski A; Blanpain C; Kuperwasser C
Cell Stem Cell; 2019 Jan; 24(1):65-78. PubMed ID: 30554963
[TBL] [Abstract][Full Text] [Related]
57. Involvement of partial EMT in cancer progression.
Saitoh M
J Biochem; 2018 Oct; 164(4):257-264. PubMed ID: 29726955
[TBL] [Abstract][Full Text] [Related]
58. Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.
Bronte G; Bravaccini S; Bronte E; Burgio MA; Rolfo C; Delmonte A; Crinò L
Biol Rev Camb Philos Soc; 2018 Nov; 93(4):1735-1746. PubMed ID: 29671943
[TBL] [Abstract][Full Text] [Related]
59. Identification of the tumour transition states occurring during EMT.
Pastushenko I; Brisebarre A; Sifrim A; Fioramonti M; Revenco T; Boumahdi S; Van Keymeulen A; Brown D; Moers V; Lemaire S; De Clercq S; Minguijón E; Balsat C; Sokolow Y; Dubois C; De Cock F; Scozzaro S; Sopena F; Lanas A; D'Haene N; Salmon I; Marine JC; Voet T; Sotiropoulou PA; Blanpain C
Nature; 2018 Apr; 556(7702):463-468. PubMed ID: 29670281
[TBL] [Abstract][Full Text] [Related]
60. Mechanism and medical implications of mammalian autophagy.
Dikic I; Elazar Z
Nat Rev Mol Cell Biol; 2018 Jun; 19(6):349-364. PubMed ID: 29618831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
